Last updated 4 days ago

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

900 patients around the world

Available in Puerto Rico, United States, Mexico, Brazil

Eli Lilly and Company

10Research sites

900Patients around the world

This study is for people with

Obesity

From 18 Years

All Gender

: Are on stable incretin therapy at screening.
With persistent obesity or overweight defined as:
≥30 kg/m2 OR
≥27 kg/m2 with at least one existing obesity related complication at screening:
Hypertension.
Dyslipidemia.
Obstructive sleep apnea.
Cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure).
Type 2 diabetes.
Have a stable body weight (<5% body weight change) at screening.

: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening).
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening).
Have type 1 diabetes.
Have taken any of the following antihyperglycemic medications within 90 days before screening:
Dipeptidyl peptidase-4 (DPP-4) inhibitors.
Amylin analogs.
Insulin.
Have had within 90 days prior to screening:
Heart attack.
Stroke.
Coronary artery revascularization.
Unstable angina.
Hospitalization due to congestive heart failure.
Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.

Quanta Diagnóstico por Imagem

R. Alm. Tamandaré, 1000 - Alto da XV, Curitiba - PR, 80045-170

Cedoes - Pesquisa e Diagnóstico

R. João da Silva Abreu, 78 - Praia do Canto, Vitória - ES, 29055-450

CPClin – Centro de Pesquisas Clinicas LTDA

Avenida Angélica, 2162 – Consolação – São Paulo, SP, CEP:01228-200

Hospital Nove de Julho

Rua Peixoto Gomide, 545 - Jardim Paulista, São Paulo - SP, 01409-001, Brazil

Centro de Diabetes Curitiba - Curitiba, Parana

Rua Alcidez Munhoz, 433, 4º andar, sala 448, Curitiba, Parana

INTEGRAL Pesquisa e Ensino

Av. da Saudade, 2147 - Parque Res. Friozi, Votuporanga - SP, 15501-405, Brasil

Private Practice - Dr. Arechavaleta Granell Maria del Rosario

Guadalajara, Jalisco, Mexico, 44670

Centro de Investigación en Artritis y Osteoporosis

Calzada de las Américas # 430 Col Cuauhtémoc sur, Mexicali Baja California 21200

Clínica García Flores

1a Avenida 507, Cumbres 1º Sector, 64610 Monterrey, N.L., Mexico

Advanced Clinical Research, LLC

Bayamon, 00960

StudyENLIGHTEN-6

SponsorEli Lilly and Company

Study typeInterventional

Conditions

Obesity

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT07392190